SOHO 2022 | Recent updates on pacritinib in myelofibrosis
Prithviraj Bose
• 30 Sep 2022
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the mechanism of action of pacritinib and its role in the treatment of myelofibrosis (MF), highlighting the recent approval of this agent. Dr Bose also discusses the results of a study which compared the safety and efficacy of pacritinib versus best available therapy (BAT) in patients in the PERSIST-2 trial (NCT02055781), emphasizing the superiority of pacritinib. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
